Evaluation of a practice team-supported, self-managed exposure training for patients with panic disorder and agoraphobia in primary care

Evaluation of a practice team-supported, self-managed exposure training for patients with panic disorder and agoraphobia in primary care - PARADISE (Patient Activation foR Anxiety DISordErs)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00004386

Enrollment

444

Registered

2012-09-25

Start date

2012-08-28

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

F41.0 F40.01

Interventions

Group 1: Intervention condition: Treatment of patients with a practice team-supported, self-managed exposure program (after training of investigating general practitioners and associated health care a

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: • Panic Disorder with or without Agoraphobia (ICD-10: F.41.0 or F40.01) • positive screening questionnaires • sufficient German language skills • private telephone

Exclusion criteria

Exclusion criteria: • acute suicidality • acute or chronic psychosis • drug or alcohol dependence • severe physical illness • pregnancy • current psychotherapeutic treatment of anxiety

Design outcomes

Primary

Measure	Time frame
Severity of anxiety, measured by the Beck Anxiety Inventory (BAI, sum of scores at measurement point T1 six months after baseline)	—

Secondary

Measure	Time frame
• Anxiety-related reduction of mobility (MI); T1/T2 • Number and severity of panic attacks (PAS, Items A1 and A2) • Depressiveness (PHQ-9); T1/T2 • Health-related quality of life (EQ-5D); T1/T2 • Quality Adjusted Life Years (EQ-5D); T1/T2 • Direct and indirect costs from a societal perspective; T1/T2 • Incremental Cost-Effectiveness Ratio (ICER); T1/T2 T1: 26 weeks after baseline T2: 52 weeks after baseline	—

Measure

Time frame

• Anxiety-related reduction of mobility (MI); T1/T2 • Number and severity of panic attacks (PAS, Items A1 and A2) • Depressiveness (PHQ-9); T1/T2 • Health-related quality of life (EQ-5D); T1/T2 • Quality Adjusted Life Years (EQ-5D); T1/T2 • Direct and indirect costs from a societal perspective; T1/T2 • Incremental Cost-Effectiveness Ratio (ICER); T1/T2 T1: 26 weeks after baseline T2: 52 weeks after baseline

—

Countries

Germany

Contacts

Public ContactThomas Hiller

Universitätsklinikum Jena, Friedrich-Schiller-Universität Institut für Allgemeinmedizin

Jena-Paradies@med.uni-jena.de03641/9-39 58 16

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 28, 2026